<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 27, 2019 (HealthDay News) — Systematic prostate-specific antigen (PSA) screening is advised for men who are carriers of the BRCA2<\/i> mutation, which is associated with a higher incidence of prostate cancer, younger age at diagnosis, and clinically significant tumors, according to the interim results of a study published in the December issue of European Urology<\/i>.<\/p>\n
Elizabeth C. Page, from the Institute of Cancer Research in London, and colleagues evaluated the utility of targeted prostate cancer screening using PSA in men with pathogenic, germline BRCA1\/2<\/i> mutations and controls (919 BRCA1<\/i> carriers, 709 BRCA1<\/i> noncarriers, 902 BRCA2<\/i> carriers, and 497 BRCA2<\/i> noncarriers).<\/p>\n
The researchers found that after three years of screening, 527 men had PSA >3.0 ng\/mL, 357 biopsies were performed, and 112 prostate cancer cases were diagnosed (31 BRCA1<\/i> carriers, 19 BRCA1<\/i> noncarriers, 47 BRCA2<\/i> carriers, and 15 BRCA2<\/i> noncarriers). In BRCA2<\/i> carriers, the cancer incidence rate was higher than in noncarriers (19.4 versus 12.0 per 1,000 person years). BRCA2<\/i> carriers were diagnosed at a younger age (61 versus 64 years) and were more likely to have clinically significant disease compared with BRCA2<\/i> noncarriers (77 versus 40 percent). There were no differences in age or tumor characteristics between BRCA1<\/i> carriers and BRCA1<\/i> noncarriers. Compared with PSA alone (area under the curve, 0.65), the 4 kallikrein marker model discriminated better (area under the curve, 0.73) for clinically significant cancer at biopsy.<\/p>\n
“We recommend that male BRCA2<\/i> carriers are offered systematic PSA screening,” the authors write.<\/p>\n
Several authors disclosed financial ties to the diagnostics industry.<\/p>\n